Pharmacyte Biotech Inc (OTCMKTS:PMCB) released the first article in a Q&A articles’ series that will be carried out with some of the prime team members of company’s planned clinical study in locally advanced, pancreatic cancer, or LAPC. First Q&A article in the planned series is with Dr. Matthias Löhr of the renowned Karolinska Institute in Stockholm. Dr. Löhr served as the Principal Investigator of the two previous clinical studies utilizing the Cell-in-a-Box® know-how in patients with LAPC.
The highlights
Commenting on PharmaCyte plans to meet with the U.S. FDA for a Pre-IND, and the Cell-in-a-Box® combined with low dose ifosfamide treatment, Dr. Löhr said that he is extremely confident and also delighted to witness the revival of this treatment idea. He believes Cell-in-a-Box® as a unique platform technology.
The initially raised issues pertaining to the constant reproducibility of the micro-capsules have been seen by Austrianova in the interim. Pancreatic cancer is a medicinal emergency and is increasing amongst the cancer associated deaths, this year beating breast cancer to list at number three, and it is projected to come at number two by 2030.
Dr. Löhr continued that when they treated the first subjects, they did not consider that they were getting chemotherapy as there witnessed no side effects in the initial study. It should be the instance in Pharmacyte’s upcoming study. Besides this subjective impression, although repeated by all subjects, they noted on the quality of life, which was superb considering the dire disease. They will be measuring the life quality in the upcoming planned study as well.
Additionally, they witnessed an effect not only on the prime tumor in the pancreas where the capsules were injected but even in some subjects on the liver metastasis. This can be described by an immunological bystander impact that will likely be checked in more depth in the imminent clinical study. Finally, in the first study, certain subjects’ tumors turned operable from inoperable. That is surely a possibility in Pharmacyte’s study, particularly since they will be giving over two courses of ifosfamide like they performed in the first study.
